Melphalan Flufenamide Emerges as Option for Heavily Pretreated Myeloma
Joseph Mikhael, MD, MEd, FRCPC, FACP, discussed how melphalan flufenamide could potentially shift the treatment paradigm for patients with multiple myeloma.
Related Articles
Personalized Dosimetry With Y-90 Glass Microspheres Shows Positive Activity in HCC
Etienne Garin, MD, PhD, details how the PROACTIF study was conducted and how Y-90 Glass Microspheres could fill an unmet need for patients with hepatocellular…
ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
FDA Grants Orphan Drug Designation to BVX001 in AML
BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.
Immunotherapy-Based Approaches Make Waves in Bladder Cancer
Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.
B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL
B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.
Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia
Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC
The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.
Clinical Benefits With Neratinib in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC
The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.